Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer

This study has been completed.

Study NCT00066625 Information provided by National Cancer Institute (NCI)

First Received: August 6, 2003 Last Updated: July 23, 2008 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	No date given

Publications:

Kobrinsky B, Kosloff RA, Wright J, et al.: Neurotoxicity assessment in a phase I bortezomib with oxaliplatin trial. [Abstract] American Association for Cancer Research: 98th Annual Meeting, April 14-18, 2007, Los Angeles, CA. A-951, 2007.

Kosloff RA, Wright J, Ivy P, et al.: Phase I study of bortezomib and oxaliplatin (BOX) in solid tumors: improved neurotoxicity (NT) profile with lower bortezomib (B) dose. [Abstract] J Clin Oncol 24 (Suppl 18): A-12007, 596s, 2006.